Results 11 to 20 of about 54,884 (249)
Adoptive T cell therapy targeting CD1 and MR1 [PDF]
Frontiers in Immunology, 2015 Adoptive T cell immunotherapy has demonstrated clinically relevant efficacy in treating malignant and infectious diseases. However, much of these therapies have been focused on enhancing, or generating de novo, effector functions of conventional T cells ...
Tingxi eGuo +4 more
doaj +3 more sources
Adoptive T-cell therapy for malignant disorders
Haematologica, 2008 Adoptive cell transfer (ACT) using ex vivo manipulated T lymphocytes has emerged as an important advance in cancer immunotherapy, allowing for re-education and re-setting of the host immune system. Recent technological advances, particularly the development of artificial antigen presenting cells (
Daniel J. Powell, Bruce L. Levine
doaj +3 more sources
Adoptive T-cell therapy of cancer. [PDF]
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2009 Adoptive immunotherapy is determined as "the isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration" and is a promising approach to inducing antitumour immune responses. Identification of tumour antigens and monitoring the persistence and transport of transferred cells has provided our ...
Ton N M, Schumacher, Nicholas P, Restifo
openaire +6 more sources
Adoptive T-cell therapy for Hodgkin lymphoma. [PDF]
Blood Adv, 2021 AbstractAlthough CAR T-cell therapy is US Food and Drug Administration–approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus–specific cytotoxic T lymphocytes and CD30 CAR T cells have ...
Ho C, Ruella M, Levine BL, Svoboda J.
europepmc +4 more sources
Adoptive T cell therapy of cancer [PDF]
Current Opinion in Immunology, 2010 Adoptive transfer of T cells specific for antigens expressed on tumor cells is an attractive strategy for producing targeted and long-lived anti-tumor activity. T cell therapies have shown activity in selected clinical applications but broader application is limited by inadequate persistence of transferred T cells and by tumor-evasion strategies ...
Malcolm K, Brenner, Helen E, Heslop
openaire +2 more sources
Adoptive T-cell therapy for Leukemia [PDF]
Molecular and Cellular Therapies, 2014 Allogeneic stem cell transplantation (alloSCT) is the most robust form of adoptive cellular therapy (ACT) and has been tremendously effective in the treatment of leukemia. It is one of the original forms of cancer immunotherapy and illustrates that lymphocytes can specifically recognize and eliminate aberrant, malignant cells.
Garber, Haven R +3 more
openaire +2 more sources
Adoptive Cell Therapy for T-Cell Malignancies
Cancers, 2022 T-cell malignancies are often aggressive and associated with poor prognoses. Adoptive cell therapy has recently shown promise as a new line of therapy for patients with hematological malignancies. However, there are currently challenges in applying adoptive cell therapy to T-cell malignancies.
Fang, Karen Kai-Lin +2 more
openaire +2 more sources
Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application
Frontiers in Oncology, 2021 Esophageal cancer is an exceedingly aggressive and malignant cancer that imposes a substantial burden on patients and their families. It is usually treated with surgery, chemotherapy, radiotherapy, and molecular-targeted therapy. Immunotherapy is a novel
Yu-Ge Zhu +5 more
doaj +1 more source
Adoptive T cell therapy for solid tumors: current landscape and future challenges. [PDF]
Front ImmunolAlbarrán V +12 more
europepmc +2 more sources
Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors
Frontiers in Immunology, 2021 Adoptive T cell therapy has emerged as a revolutionary immunotherapy for treating cancer. Despite immense promise and clinical success in some hematologic malignancies, limitations remain that thwart its efficacy in solid tumors.
Preethi Bala Balakrishnan +1 more
doaj +1 more source